TNFSF10 and familial pancreatic carcinoma: Olaparib and TRAIL significantly inhibited the proliferation of two organoids derived from pancreatic cancer patients compared with olaparib alone, (Figure 7, PDO-1 and PDO-2), while in a third organoid (PDO-3) the addition of TRAIL did not improve the efficacy of olaparib (Figure 7, PDO-3).